ライフサイエンスコーパス: HDL cholesterol

1 olic blood pressure [SBP/DBP], total [TC] or HDL-cholesterol).

2 associates with CAD after accounting for non-HDL cholesterol.

3 by rs2246293 genotypes in the EPA-associated HDL cholesterol.

4 not with age, sex, duration of diabetes, or HDL cholesterol.

5 T), red blood cell indices (MCH and MCV) and HDL cholesterol.

6 , effects that were attributable to elevated HDL cholesterol.

7 low-mediated dilation, and total cholesterol/HDL cholesterol.

8 ount, multiple sclerosis, celiac disease and HDL cholesterol.

9 r apolipoprotein B, triacylglycerols, and TC/HDL cholesterol.

10 lso associated with higher rather than lower HDL cholesterol.

11 levels were also positively associated with HDL cholesterol.

12 rdiovascular disease that are independent of HDL-cholesterol.

13 3-1.44) per 1 standard deviation increase in HDL-cholesterol.

14 gonist GW501516 to increase plasma levels of HDL-cholesterol.

15 oprotein (LDL) and high-density lipoprotein (HDL) cholesterol.

16 ion was shown with high-density lipoprotein (HDL) cholesterol.

17 y lipoprotein, and high-density lipoprotein (HDL) cholesterol].

18 -0.00761--0.0027), high density lipoprotein (HDL) cholesterol 0.00179 (95% CI 0.000571-0.00301), trig

19 re (-2.48 mm Hg; 95% CI: -4.98, 0.02 mm Hg), HDL cholesterol (0.12 mmol/L; 95% CI: -0.03, 0.28 mmol/L

20 ta-carotene and BMI (-0.27), WC (-0.30), and HDL cholesterol (0.31) after accounting for multiple com

21 10 mmol/L, respectively (P = 0.007); and non-HDL cholesterol: +0.24 +/- 0.49 compared with -0.14 +/-

22 olesterol (-17 +/- 4 mg/dL; P < 0.0001), non-HDL cholesterol (-16 +/- 3 mg/dL; P < 0.0001), triglycer

23 elevated blood pressure, 40.98% for reduced HDL-cholesterol, 23.33% for elevated triglycerides, 18.9

24 4.1% compared with 0.9%; P < 0.0001) and non-HDL cholesterol (-3.1% compared with 0.4%; P = 0.0032).

25 2% (95% CI: -2.3%, 7.8%), respectively], non-HDL cholesterol [-5.3% (95% CI: -8.6%, 2.1%) compared wi

26 ocumab was associated with reductions in non-HDL cholesterol (55% [47-63] vs placebo and 34% [26-41]

27 6% [16-35] vs ezetimibe), and an increase in HDL cholesterol (7% [4-11] vs placebo and 8% [4-13] vs e

28 ctively; P = 0.006) and greater increases in HDL cholesterol (7.6% +/- 1.4% compared with -0.7% +/- 1

29 % CI, -13.3 to +10.2; P=0.80), but increased HDL cholesterol (+7.7%), apolipoprotein A-I (+4.3%), and

30 .24 to -0.13) and positive correlations with HDL cholesterol (alpha-carotene = 0.17; beta-carotene =

31 region associated with increased circulating HDL-cholesterol also associate with increased AMD risk,

32 cy was associated with reduced levels of non-HDL cholesterol and a reduced risk of coronary artery di

33 meat as primary sources of SFAs cause higher HDL cholesterol and apo A-I and, therefore, appear to be

34 HDL cholesterol and apoA1 and apoC3 quartiles were not r

35 howed significantly higher concentrations of HDL cholesterol and apolipoprotein A-I and significantly

36 ntrast with significant associations for non-HDL cholesterol and atherogenic particles: apolipoprotei

37 We assessed changes in HbA1c, triglycerides, HDL cholesterol and BMI in a mixed effects longitudinal

38 The lack of an association between HDL cholesterol and cardiovascular risk may support the

39 stigated the association between primary low HDL cholesterol and coronary heart disease (CHD), CVD, a

40 Alcohol also increases HDL cholesterol and lowers LDL cholesterol.

41 t Study [n=5835]) were screened for combined HDL cholesterol and Lp(a) elevations.

42 In an index subject with high levels of HDL cholesterol and Lp(a), SCARB1 was sequenced and demo

43 notype, characterized by high levels of both HDL cholesterol and Lp(a).

44 that signals observed at ABCA1 and LIPC for HDL cholesterol and NCAN/MAU2 for triglycerides are inde

45 HDL cholesterol and triglyceride also showed significant

46 no significant differences between diets for HDL cholesterol and triglyceride.In comparison with a co

47 .9% of the variability of total cholesterol, HDL cholesterol and triglycerides in the Framingham Offs

48 for potentially mediating factors, including HDL cholesterol and triglycerides, coronary risk remaine

49 Serum levels of high-density lipoprotein (HDL) cholesterol and apolipoprotein A-I (apoA-I) were po

50 A than after iTFA; high-density lipoprotein (HDL) cholesterol and apolipoprotein AI also were higher

51 ween low levels of high-density lipoprotein (HDL) cholesterol and cardiovascular disease (CVD) have o

52 ol may explain variable correlations between HDL-cholesterol and cardiovascular risk and inform futur

53 formed on kidney function (defined by eGFR), HDL-cholesterol and triglycerides.

54 igher TC, LDL cholesterol, apolipoprotein B, HDL cholesterol, and apolipoprotein A-I, whereas most of

55 ncreased TC, LDL cholesterol, ratio of TC to HDL cholesterol, and apolipoprotein B (2-6% change; P <

56 ss the effect of KJM on LDL cholesterol, non-HDL cholesterol, and apolipoprotein B.Medline, Embase, C

57 were associated with on-treatment LDL-C, non-HDL cholesterol, and apolipoprotein B; these were also a

58 nt of high-density lipoprotein (HDL) and non-HDL cholesterol, and extended to stroke and myocardial i

59 CD36 along with an increase in fatty acids, HDL cholesterol, and glucose in the blood.

60 development of glucose intolerance, reduced HDL cholesterol, and increased levels of leptin and MCP-

61 DL-free cholesterol, XL-HDL phospholipids, L-HDL cholesterol, and L-HDL-free cholesterol, as well as

62 insulin, C-reactive protein, interleukin-6, HDL cholesterol, and triglycerides in a nonstratified an

63 with systolic and diastolic blood pressure, HDL cholesterol, and triglycerides were included as cova

64 pid panels including total cholesterol (TC), HDL cholesterol, and triglycerides were measured at base

65 in total cholesterol (TC), LDL cholesterol, HDL cholesterol, and triglycerides.

66 (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides; and systolic blood

67 assess the causal roles of LDL-cholesterol, HDL-cholesterol, and triglycerides on AMD risk.

68 flux capacity was moderately correlated with HDL cholesterol, apolipoprotein A-I, and HDL particle nu

69 diet, significantly reduced LDL cholesterol, HDL cholesterol, apolipoprotein A-I, intermediate-densit

70 B (2-6% change; P < 0.05); VA also increased HDL cholesterol, apolipoprotein AI, apolipoprotein B, an

71 Higher levels of HDL cholesterol appear to protect against RHOA after 11

72 Whether levels of HDL cholesterol are causally associated with type 2 diab

73 High concentrations of HDL cholesterol are considered to indicate efficient rev

74 Observationally, low levels of HDL cholesterol are consistently associated with increas

75 alcohol consumption with blood pressure and HDL-cholesterol are causal.

76 It can be concluded that HDL cholesterol as a trait is genetically heterogeneous,

77 eterozygotes of gene variants are known, and HDL cholesterol as a trait is inherited in an autosomal-

78 We defined "primary low HDL cholesterol" as HDL cholesterol level <40 mg/dL (men

79 The difference in HDL cholesterol associated with higher circulating EPA w

80 lesterol, triglycerides, lipoprotein(a), and HDL cholesterol at 12 weeks for evolocumab, placebo, and

81 rides (beta = 0.018; P = 4 x 10(-29)), lower HDL cholesterol (beta = -0.020; P = 7 x 10(-37)), greate

82 reduction was associated with an increase in HDL cholesterol (beta = -0.452; 95% CI: -0.880, -0.023;

83 039) and a decrease in total cholesterol and HDL cholesterol (beta = 3.766; 95% CI: 1.092, 6.440; P =

84 he ratio of TGs to high-density lipoprotein (HDL) cholesterol (beta = 2.689; 95% CI: 0.373, 5.003; P

85 There was no significant difference in HDL cholesterol between the REG and RED diets, but HDL c

86 erides and only 1-3% of the association with HDL-cholesterol, blood pressure, and insulin concentrati

87 Age, smoking, plasma HDL cholesterol, BMI, and female sex are associated with

88 systolic blood pressure, LDL cholesterol, or HDL cholesterol but did lower triglycerides from 111 to

89 rom cheese and butter has similar effects on HDL cholesterol but differentially modifies LDL-choleste

90 h coronary heart disease after adjusting for HDL cholesterol, but its effect on incident coronary hea

91 y lipoprotein, and high-density lipoprotein (HDL) cholesterol, but not in the total-to-HDL cholestero

92 LPL, ABCA1, ZNF259/APOA5, LIPC and CETP for HDL cholesterol, CELSR2, APOB and NCAN/MAU2 for LDL chol

93 urthermore, thermogenic stimulation promotes HDL-cholesterol clearance and increases macrophage-to-fa

94 r intake was also followed by an increase in HDL cholesterol compared with the habitual diet.

95 05 and P < 0.05, respectively) and increased HDL cholesterol compared with the run-in period (P < 0.0

96 flux capacity was positively correlated with HDL cholesterol concentration (r=0.40; p<0.0001) and apo

97 rovided smaller estimates of the mean plasma HDL cholesterol concentration in association with both t

98 apeutic modulation of the HDL pathway beyond HDL cholesterol concentration to help reduce risk of cor

99 is unclear whether high-density lipoprotein (HDL) cholesterol concentration plays a causal role in at

100 caused a 5% higher high-density lipoprotein (HDL)-cholesterol concentration (P = 0.012), an 8% higher

101 Also, the MEAT diet caused an 8% higher HDL-cholesterol concentration (P < 0.001) and a 4% highe

102 The non-HDL-cholesterol concentration and total cholesterol:HDL-

103 r demographic and lifestyle factors, the non-HDL-cholesterol concentration was significantly lower in

104 There was no change in HDL-cholesterol concentration, but triglyceride concentr

105 CC control and LFHCC n-3 diets and increased HDL cholesterol concentrations after consumption of the

106 Although HDL cholesterol concentrations are strongly and inversel

107 erolemic (HL) diet for 10 days, reaching non-HDL cholesterol concentrations of 38.2 +/- 3.5 mg/dl and

108 Mean LDL and HDL cholesterol concentrations were 2.35 mmol/L (91 mg/d

109 Although HDL cholesterol concentrations were similar to wild-type

110 ociated with plasma adiponectin, insulin and HDL cholesterol concentrations, obesity, and coronary at

111 ) single nucleotide polymorphisms and plasma HDL cholesterol concentrations.

112 r risk that extend beyond traditional plasma HDL cholesterol concentrations.

113 en with abdominal obesity and relatively low HDL-cholesterol concentrations were assigned to sequence

114 rbohydrate diet (fat: 25%, SFAs: 5.8%).Serum HDL-cholesterol concentrations were similar after the ch

115 Lipid biomarkers, such as HDL-cholesterol concentrations, have been shown to have

116 Both products increased HDL-cholesterol concentrations, whereas only DFCP decrea

117 ower LDL-cholesterol concentrations or raise HDL-cholesterol concentrations.

118 The genetic risk score for non-HDL cholesterol confers CAD risk beyond that of LDL chol

119 Low levels of high-density lipoprotein (HDL) cholesterol constitutes a major risk factor for ath

120 /apoB-100 dual transgenic mice and increased HDL cholesterol content and size comparable to torcetrap

121 t plasma levels of high-density lipoprotein (HDL) cholesterol correlate inversely with cardiovascular

122 HDL cholesterol-decreasing gene scores and allele number

123 re 0.91 (0.75-1.09) and 0.93 (0.78-1.11) for HDL cholesterol-decreasing gene scores and allele number

124 enger receptor B-I are the driving forces of HDL-cholesterol disposal in liver.

125 nary heart disease, interventions that raise HDL cholesterol do not reduce risk of coronary heart dis

126 In conclusion, genetically reduced HDL cholesterol does not associate with increased risk o

127 ucose effect was stronger (P = 0.01) and the HDL-cholesterol effect was no longer significant (P = 0.

128 We investigated whether HDL cholesterol efflux capacity is associated with cardi

129 In conclusion, HDL cholesterol efflux capacity is not a prognostic card

130 tudy (4D Study), we investigated whether the HDL cholesterol efflux capacity is predictive for cardio

131 HDL cholesterol efflux capacity might provide an alterna

132 HDL cholesterol efflux capacity-a prototypical measure o

133 In conclusion, HDL-cholesterol efflux normalised to apoA-I was inversel

134 -reactive protein, high-density lipoprotein (HDL) cholesterol, forced expiratory volume, grip strengt

135 anges in the abundance of biomarkers such as HDL cholesterol, free fatty acids, FGF21, bilirubin, and

136 CanolaDHA was the only diet that increased HDL cholesterol from baseline (3.5 +/- 1.8%; P < 0.05) a

137 was percentage change in LDL cholesterol and HDL cholesterol from baseline at week 12, analysed by in

138 s no significant difference in the change in HDL cholesterol from screening to 3 mo between groups; t

139 The non-HDL cholesterol genetic risk score associates most stron

140 We defined an "optimal" lipid profile as HDL cholesterol >/=40 mg/dL (men) or >/=50 mg/dL (women)

141 Participants with primary low HDL cholesterol had higher risks of CHD and CVD than par

142 e LIPC gene region that increase circulating HDL-cholesterol have the opposite direction of associati

143 In the general population, HDL cholesterol (HDL-C) is associated with reduced cardi

144 ctor 14 (KLF14) are strongly associated with HDL cholesterol (HDL-C) levels, metabolic syndrome, and

145 The cholesterol concentration of HDL (HDL cholesterol (HDL-C)) without apoC-III was inversely

146 (HbA1c), insulin resistance, triglycerides, HDL cholesterol (HDL-C), and C-reactive protein].

147 to estimate associations between circulating HDL cholesterol (HDL-C), LDL cholesterol (LDL-C), and tr

148 major receptor for high-density lipoprotein (HDL) cholesterol (HDL-C).

149 terol efflux and are associated with reduced HDL-cholesterol (HDL-C) levels.

150 The recent failures of HDL-cholesterol (HDL-C) raising therapies have initiated

151 oncentration predict coronary ED better than HDL-cholesterol (HDL-C).

152 -frequency variants for association with non-HDL cholesterol, HDL cholesterol, LDL cholesterol, and t

153 Postprandial triacylglycerol, HDL-cholesterol, HDL(3)-cholesterol, and glucose concent

154 tor profile [lower high-density lipoprotein (HDL) cholesterol, higher total homocysteine, and higher

155 ; P-trend = 0.006) and lung cancer risk with HDL cholesterol (HR: 0.59; 95% CI: 0.38, 0.93; P-trend =

156 iations included colorectal cancer risk with HDL cholesterol (HR: 0.63; 95% CI; 0.41, 0.98; P-trend =

157 9; 95% CI: 0.70, 0.90; P-trend = 0.0008) and HDL cholesterol (HR: 0.85; 95% CI: 0.75, 0.97; P-trend =

158 d for baseline non-high-density lipoprotein (HDL) cholesterol (HR, 1.18; 95% CI, 1.01-1.38), apolipop

159 ey had <2 of the following risk factors: low HDL cholesterol, hypertension, high blood glucose, high

160 e function of CETP can increase the level of HDL cholesterol in blood plasma and suppress the risk of

161 tolic blood pressure and decreased total and HDL cholesterol in males.

162 d the elevated ratio of total cholesterol to HDL cholesterol in the fasted serum (P = 0.03) and postp

163 9) in the ENCODE consortium and lower plasma HDL cholesterol in the GOLDN study (r = -0.12, P = 0.000

164 The causal role of high-density lipoprotein (HDL) cholesterol in cardioprotection has been questioned

165 cause low levels of LDL-cholesterol and low HDL-cholesterol in compound heterozygotes and homozygous

166 les, in particular high-density lipoprotein (HDL) cholesterol, in overweight or obese people with pre

167 rongly correlated to plasma triglyceride and HDL-cholesterol, including at CD36.

168 and risks including acne, alopecia, reduced HDL cholesterol, increased triglycerides, and a possible

169 Therefore, plasma HDL cholesterol increasing has been suggested as a novel

170 Some genetic evidence suggests that HDL-cholesterol is a causal risk factor for AMD risk and

171 We find evidence that HDL-cholesterol is a causal risk factor for AMD, with an

172 .001] and greater mean (95% CI) increases in HDL cholesterol [LC diet: 0.1 mmol/L (0.1, 0.2 mmol/L);

173 There were significant increases in HDL cholesterol, LDL cholesterol, and triacylglycerols,

174 ts for association with non-HDL cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides in u

175 sitivity C-reactive protein, hemoglobin A1c, HDL cholesterol, LDL cholesterol, and triglycerides, the

176 ng and/or postprandial concentrations of non-HDL cholesterol, LDL cholesterol, apolipoprotein B, apol

177 th increased apolipoprotein B fractions (non-HDL cholesterol, LDL cholesterol, triglycerides, and apo

178 We defined "primary low HDL cholesterol" as HDL cholesterol level <40 mg/dL (men) or <50 mg/dL (wome

179 mg/dL}]; P = 0.038) and greater increases in HDL cholesterol level (mean difference in change, 0.18 m

180 deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol

181 deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol

182 ured in the central laboratory) lower and an HDL cholesterol level that was an average of 6 mg per de

183 Baseline HDL cholesterol level was not associated with cardiovasc

184 We measured HDL cholesterol level, HDL particle concentration, and c

185 ty of obesity, the higher the risks of a low HDL cholesterol level, high systolic and diastolic blood

186 1.04-1.79), plasma high-density lipoprotein (HDL) cholesterol level (OR, 1.62 per mmol/L; 95% CI, 1.1

187 vel and raises the high-density lipoprotein (HDL) cholesterol level, but its clinical efficacy and sa

188 .13, 95% CI: 1.05, 1.21) and 10-mg/dL-higher HDL cholesterol levels (odds ratio = 0.96, 95% CI: 0.92,

189 associated with sPTB: 1) increasing NEFA and HDL cholesterol levels and 2) family history of gestatio

190 sting insulin levels adjusted for BMI, lower HDL cholesterol levels and higher triglyceride levels) a

191 An inverse association between HDL cholesterol levels and the incidence of RHOA was obs

192 lso had lower triglyceride levels and higher HDL cholesterol levels and were less likely to have coro

193 ed genetic variants were associated with low HDL cholesterol levels and, in turn, with an increased r

194 ol levels between 2.5 mmol/L and 4.5 mmol/L, HDL cholesterol levels between 0.8 and 1.8 mmol/L and tr

195 otect from coronary heart disease, increases HDL cholesterol levels by 0.17 mmol l(-1) (P=5.82 x 10(-

196 A daily dose of 1 mg TA-8995 increased HDL cholesterol levels by 75.8%, 2.5 mg by 124.3%, 5 mg

197 ation between these imputed variants and non-HDL cholesterol levels in 119,146 samples.

198 with HDL but positively correlated with non-HDL cholesterol levels in F2 mice on either chow or West

199 ictor of graft failure independent of plasma HDL cholesterol levels in renal transplant recipients.

200 ceiving 10 mg TA-8995 and 20 mg atorvastatin HDL cholesterol levels increased by 152.1% and in patien

201 HDL cholesterol levels, apolipoprotein A-I, cholesterol

202 s of which include hypertriglyceridemia, low HDL cholesterol levels, qualitative changes in LDL parti

203 features, such as severe fatty liver and low HDL cholesterol levels, that are predicted by the result

204 l transporter could link hsa-miR-885-5p with HDL cholesterol levels.

205 ciated with up to -13 and -20% reductions in HDL cholesterol levels.

206 ty lipoprotein) and a suggestive QTL for non-HDL cholesterol levels.

207 64-0.88; Ptrend = 0.030) for having abnormal HDL cholesterol levels.

208 elate with high plasma triglycerides and low HDL cholesterol levels.

209 in-containing oxidoreductase (WWOX) gene and HDL cholesterol levels.

210 role of the lipoprotein beyond quantitative HDL cholesterol levels.

211 R-885-5p levels associated inversely with XL HDL cholesterol levels.

212 lationship between high-density lipoprotein (HDL) cholesterol levels and cardiovascular disease, ongo

213 new experience and high-density lipoprotein (HDL) cholesterol levels are most positively genetically

214 drugs that raised high-density lipoprotein (HDL) cholesterol levels to reduce cardiovascular events

215 vels and increases high-density lipoprotein (HDL) cholesterol levels.

216 ces remained significant after adjusting for HDL-cholesterol levels.

217 total cholesterol (FN1 and SAMM50), two for HDL cholesterol (LOC100996634 and COPB1) and one for LDL

218 scores and polygenic profile scores for BMI, HDL cholesterol, low-density lipoprotein cholesterol, co

219 total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) choleste

220 total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein cholesterol, t

221 cardiometabolic risk-factor profile (higher HDL cholesterol, lower BMI, lower C-reactive protein, lo

222 astolic >/= 85 mm Hg, or antihypertensives); HDL cholesterol < 40 mg/dL (men) or < 50 mg/dL (women);

223 pattern suggesting that NEFAs together with HDL cholesterol may be related to sPTB.

224 prevention, which reduce apo B-100 or raise HDL cholesterol, may be associated with reduced cancer r

225 mmol/L; 95% CI: -0.46, -0.25 mmol/L) and non-HDL cholesterol (MD: -0.32 mmol/L; 95% CI: -0.46, -0.19

226 , 21.5), and lower high-density lipoprotein (HDL) cholesterol (MD = -2.1 mg/dL, 95% CI: -2.7, -1.6) c

227 1), ratio of total-high-density lipoprotein (HDL) cholesterol (mean difference in change, -0.44 [CI,

228 gnificant differences for total cholesterol, HDL-cholesterol, non-HDL-cholesterol, triglycerides, hig

229 NSNPs = 32), total cholesterol (NSNPs = 73), HDL-cholesterol (NSNPs = 71), LDL-cholesterol (NSNPs = 5

230 /d for reductions in LDL cholesterol and non-HDL cholesterol of 10% and 7%, respectively.

231 n objective was to investigate the effect of HDL cholesterol on outcomes in maintenance hemodialysis

232 sterol concentration, log-triglycerides, and HDL cholesterol or apoA-I concentrations (odds ratio 0.6

233 diets lowers LDL cholesterol and TC, but not HDL cholesterol or triglycerides, compared with consumpt

234 ps or between groups for changes in total or HDL cholesterol or triglycerides.

235 0.30 mmol/L, respectively, without changing HDL cholesterol or triglycerides.

236 ty (OR/SD, 0.89; 95% CI, 0.72-1.10; P=0.28), HDL cholesterol (OR/SD, 0.82; 95% CI, 0.66-1.02; P=0.08)

237 ed the effect of KJM on LDL cholesterol, non-HDL cholesterol, or apolipoprotein B.

238 P<0.001) independent of apolipoprotein A-I, HDL cholesterol, or creatinine clearance.

239 k index, total cholesterol, LDL cholesterol, HDL cholesterol, or triglycerides (all P > 0.05).

240 (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, or triglycerides at a genome-wide leve

241 Both glucose (P = 0.02) and HDL cholesterol (P = 0.04) were lower with the consumpti

242 (P = 0.03), LDL cholesterol (P = 0.04), and HDL cholesterol (P = 0.05) than placebo toothpaste.

243 No changes were observed for HDL cholesterol (P = 0.30), C-reactive protein (P = 0.10

244 EBF1 expression was directly associated with HDL cholesterol (P-value = 0.0429).

245 was also associated with lower levels of non-HDL cholesterol (P=1.8x10(-3)).

246 ycerides and lower high-density lipoprotein (HDL) cholesterol (P = 0.06).

247 e, only rs1729407 showed an association with HDL-cholesterol (P = 7.1 x 10 (-) (07)).

248 risk factor for AMD risk and that increasing HDL-cholesterol (particularly via CETP inhibition) will

249 ation related to total cholesterol (SREBF2), HDL-cholesterol (PHOSPHO1, SYNGAP1 and an intergenic reg

250 lder and had lower high-density lipoprotein (HDL) cholesterol, phospholipids, and methylation potenti

251 ] was not significant, the total cholesterol:HDL cholesterol ratio was 0.13 (95% CI: 0, 0.26; P = 0.0

252 re, heart rate, HbA1c, blood glucose, LDL-to-HDL cholesterol ratio, C-reactive protein, angiotensin I

253 n (HDL) cholesterol, but not in the total-to-HDL cholesterol ratio.

254 respectively; P = 0.005) and the cholesterol:HDL-cholesterol ratio (-2.5% +/- 1.3% compared with 0.3%

255 tin use in relation to the total cholesterol:HDL-cholesterol ratio (P-interaction = 0.04) and elevate

256 %), respectively], and the total-cholesterol:HDL-cholesterol ratio [-0.0% (95% CI: -4.3%, 4.8%) compa

257 lesterol concentration and total cholesterol:HDL-cholesterol ratio were calculated.

258 tus, diabetes duration, total cholesterol to HDL-cholesterol ratio, smoking, systolic blood pressure,

259 change from baseline in total cholesterol to HDL-cholesterol ratio.

260 l population (n = 47,627), we tested whether HDL cholesterol-related genetic variants were associated

261 ith LDL cholesterol (rs17242388 in LDLR) and HDL cholesterol (rs189679427 between GOT2 and APOOP5), a

262 lesterol, HDL cholesterol, triglycerides, TC:HDL cholesterol, SBP, and DBP, respectively].

263 erol, and L-HDL-free cholesterol, as well as HDL cholesterol seem to be protective against increasing

264 nce, triglyceride, high-density lipoprotein (HDL) cholesterol, systolic and diastolic blood pressure,

265 L cholesterol, triglycerides, ratio of TC to HDL cholesterol (TC:HDL), and systolic and diastolic blo

266 Among all subjects, TC, LDL cholesterol, HDL cholesterol, TC:HDL cholesterol, triglycerides, and

267 tintervention values of TC, LDL cholesterol, HDL cholesterol, TC:HDL cholesterol, triglycerides, SBP,

268 olesterol between the REG and RED diets, but HDL cholesterol tended to be higher with the REG diet th

269 levels of triglycerides and higher levels of HDL cholesterol than did heterozygotes.

270 ociated with decreased adiposity and greater HDL cholesterol than lower protein diets.

271 r study population) had a lower level of non-HDL cholesterol than noncarriers, a difference of 15.3 m

272 erum levels of non-high-density lipoprotein (HDL) cholesterol that alter the risk of coronary artery

273 articipants than in female participants; for HDL cholesterol, the mean values were lower with greater

274 d diastolic blood pressure, LDL cholesterol, HDL cholesterol, total cholesterol, triglycerides, and f

275 ne in concentrations of LDL cholesterol, non-HDL cholesterol, total cholesterol, triglycerides, lipop

276 (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triacylglycerols, apolipoproteins A-I

277 HDL-cholesterol, triglyceride, sitosterol, lathosterol,

278 traits (total cholesterol, LDL-cholesterol, HDL-cholesterol triglycerides) in up to 27 312 individua

279 laDHA, a novel DHA-rich canola oil, improves HDL cholesterol, triglycerides, and blood pressure, ther

280 ts, TC, LDL cholesterol, HDL cholesterol, TC:HDL cholesterol, triglycerides, and DBP, but not SBP, de

281 tes for low-density lipoprotein cholesterol, HDL cholesterol, triglycerides, glucose, and body mass i

282 %, P </= .001); and did not affect levels of HDL cholesterol, triglycerides, or blood pressure.

283 ood total cholesterol (TC), LDL cholesterol, HDL cholesterol, triglycerides, ratio of TC to HDL chole

284 of TC, LDL cholesterol, HDL cholesterol, TC:HDL cholesterol, triglycerides, SBP, and DBP; calculated

285 g (-1.2, 1.5 mm Hg) for TC, LDL cholesterol, HDL cholesterol, triglycerides, TC:HDL cholesterol, SBP,

286 ty lipoprotein and high-density lipoprotein (HDL) cholesterol, triglycerides, and uric acid were also

287 ircumference (WC), high-density lipoprotein (HDL) cholesterol, triglycerides, fat mass (FM), systolic

288 for total cholesterol, HDL-cholesterol, non-HDL-cholesterol, triglycerides, high sensitivity C-react

289 processing of SR-BI and abrogates selective HDL cholesterol uptake in transfected cells, in hepatocy

290 For participants with primary low HDL cholesterol versus those with an optimal lipid profi

291 orts in the CHARGE consortium, higher plasma HDL cholesterol was associated with fewer C alleles at A

292 At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12

293 fference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 m

294 No effect of whole-grain foods on HDL cholesterol was seen, whereas whole-grain foods tend

295 ype 2 diabetes for a 0.2 mmol/L reduction in HDL cholesterol were 0.91 (0.75-1.09) and 0.93 (0.78-1.1

296 Body mass index and HDL cholesterol were negatively correlated with molecula

297 and the levels of high-density lipoprotein (HDL) cholesterol were 7% higher among carriers of the E4

298 L) cholesterol and high-density lipoprotein (HDL) cholesterol were highest, and triglycerides were lo

299 peared to be responsible for the increase in HDL-cholesterol, whereas insoluble-dietary-fibre and the

300 ra large (XL) HDL lipid components, i.e., XL-HDL cholesterol, XL-HDL-free cholesterol, XL-HDL phospho